Zolgensma is the brand name for onasemnogene abeparvovec-xioi, a one-time gene replacement therapy made by Novartis Gene Therapies for children under 2 years old with spinal muscular atrophy (SMA) and a confirmed mutation in the SMN1 gene. The FDA approved it in May 2019 as an intravenous infusion given over about one hour. The Novartis list price in 2026 is $2,125,000 per dose, set at launch on the argument that a single treatment replaces years of chronic therapy. Because the dose is weight-based and shipped to a treatment center, no pharmacy counter sells it, and no family shops for it the way they would for a monthly prescription. Payment flows through a hospital, a specialty pharmacy such as Accredo, and the child's health plan.
Coverage for Zolgensma in 2026 depends almost entirely on the child's insurance type. Commercial plans cover it under the medical benefit with prior authorization and a formulary tier or exclusion review, and the family owes only the plan's out-of-pocket maximum. State Medicaid programs and CHIP cover it as well, often after a state prior authorization policy update, and federal EPSDT rules require Medicaid to cover medically necessary treatment for enrolled children under 21. Novartis also offers pay-over-time (five payments of $425,000) and outcomes-based agreements to payers, so a plan's actual cost can be lower than the list price. Families who cannot get coverage can apply to the Novartis Patient Assistance Foundation. Households comparing income tests should review Medicaid income limits and the federal poverty level tables.
Novartis approved a second product in November 2025: Itvisma (onasemnogene abeparvovec-brve), an intrathecal injection for patients with SMA who are 2 years of age and older. Novartis set the 2026 wholesale acquisition cost of Itvisma at $2,590,000. Zolgensma remains the intravenous product for children under 2. Neither product is on the Medicare drug price negotiation list, so no Maximum Fair Price applies to either one in 2026. The Inflation Reduction Act negotiation program targets high-spend Medicare Part D and Part B drugs, and a one-time pediatric therapy generates very little Medicare spending. Families weighing options should also compare the chronic SMA drugs Spinraza (nusinersen) and Evrysdi (risdiplam), which are given for life rather than once.
What Zolgensma Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same zolgensma can cost many times more at a hospital than at your local pharmacy:
2026 Zolgensma Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Specialty pharmacy or hospital list price (2026) | $2,125,000 one-time (no retail counter price) | Novartis wholesale acquisition cost in 2026; pay-over-time is five payments of $425,000 for payers. |
| Commercial insurance (2026) | $0 to your plan's 2026 out-of-pocket maximum | Prior authorization is required. The 2026 federal out-of-pocket limit for ACA-compliant plans is $10,600 individual and $21,200 family. |
| Novartis CopayAssist (commercial only, 2026) | Covers deductible, copay, and coinsurance up to a program maximum | Not valid with Medicare, Medicaid, or other federal or state programs; valid 1 year from enrollment. |
| Medicaid or CHIP (2026) | $0 to $4 nominal copay, if any | State prior authorization applies; EPSDT requires coverage of medically necessary care for enrolled children under 21. |
| Medicare (2026) | Rarely applicable; Part D 2026 cap is $2,100 | Treatment occurs under age 2; billed under the medical benefit with J3399 when Part B applies. |
Zolgensma cost by coverage type (2026). Figures reflect the Novartis list price and 2026 federal out-of-pocket rules; your plan's actual contract price may differ.
Source: Novartis, CMS, HealthCare.gov, Medicaid.gov, Novartis Patient Support
Why Hospitals Charge So Much
Zolgensma reaches hospitals as a frozen-shipped, weight-based kit that must be infused within a narrow window, so the hospital or specialty pharmacy carries inventory risk on a $2,125,000 product in 2026. Hospitals that buy and bill the drug add a facility markup on top of the acquisition cost, and chargemaster prices for the same drug can differ by hundreds of thousands of dollars between systems. The infusion itself takes about one hour, but the surrounding care includes pre-infusion liver testing, a corticosteroid regimen, and weekly liver monitoring for roughly the first months, all billed separately from the drug.
Families who receive an itemized bill or explanation of benefits showing more than the contracted rate should request the line-item drug charge, the J3399 billing units, and the National Drug Code. Insurers usually pay the negotiated contract rate or the Novartis acquisition cost plus a set percentage, not the chargemaster amount, so a balance-billed difference is often a dispute target. The medical bill analyzer can flag duplicate drug lines, wrong units, and out-of-network facility fees before you pay a single dollar in 2026. Treatment centers in the Novartis network also handle most insurance verification, which reduces surprise bills.
HCPCS J-Codes: What Appears on Your Bill
Zolgensma is billed under the medical benefit with a single HCPCS Level II J-code in 2026. Check that the code and units on your bill match one treatment.
HCPCS J-codes for Zolgensma| Code | Description | What to look for |
|---|
| J3399 | Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes | Billing units should be 1 (one treatment). Multiple units or a repeat J3399 claim is an error, since Zolgensma is a one-time therapy. |
Itvisma is a separate product with its own billing code; do not confuse it with J3399 in 2026.
Source: CMS HCPCS Level II coding, https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price
Patient Assistance Programs
Novartis runs two programs for Zolgensma families in 2026. An uninsured family facing a one-time list price of $2,125,000 cannot pay, and the Novartis Patient Assistance Foundation can supply Zolgensma at no cost to those who meet its income and insurance guidelines. Commercially insured families use CopayAssist for deductible and coinsurance costs instead.
Patient assistance programs for Zolgensma| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Novartis Patient Assistance Foundation (NPAF), including the OneGene Program | Free Zolgensma for eligible uninsured or underinsured families under NPAF income guidelines | pap.novartis.com |
| Novartis Patient Support (case coordinators) | Insurance verification, prior authorization support, and financial support navigation | zolgensma.com/patient-support or 855-441-4363 |
| Zolgensma and Itvisma CopayAssist | Covers deductible, copay, and coinsurance for commercially insured patients, up to a program maximum, valid 1 year | zolgensma-itvisma-copayassist.com |
| NeedyMeds | Directory of additional SMA family assistance and travel support | needymeds.org |
If you have Medicare, Medicaid, TRICARE, or VA coverage, manufacturer copay cards such as CopayAssist are blocked by the federal anti-kickback statute (42 U.S.C. § 1320a-7b). Use the income-based Novartis Patient Assistance Foundation program or your state Medicaid benefit instead. A manufacturer coupon can never be combined with government insurance.
Source: Novartis Patient Assistance Foundation (pap.novartis.com), Novartis Patient Support (zolgensma.com/patient-support), NeedyMeds.org
Medicare Part D
Medicare Part D is unlikely to pay for Zolgensma in 2026 because the therapy is given as an infusion before age 2, when almost no patient has Medicare, and it is normally handled under the medical benefit rather than a pharmacy benefit. When Medicare Part B applies to a patient of any age, the drug is billed with J3399 and paid at the Average Sales Price plus 6 percent, with 20 percent coinsurance after the 2026 Part B deductible of $283. Any Part D drug that a patient does take is subject to the 2026 annual out-of-pocket cap of $2,100, established by the Inflation Reduction Act.
Medicare beneficiaries who are adults with SMA typically fall under Itvisma or chronic SMA drugs rather than Zolgensma, and plan formulary tier placement and prior authorization rules decide what they pay. The Maximum Fair Price program does not include Zolgensma in 2026, so no negotiated Medicare price applies. Beneficiaries can spread costs with the Medicare Prescription Payment Plan for Part D drugs, and can check plan rules at Medicare.gov. Children with disabilities who qualify for both Medicaid and Medicare should ask their state Medicaid agency which program is primary payer before treatment is scheduled.
Common Zolgensma Billing Errors
If a Zolgensma bill or explanation of benefits shows a balance owed above your plan's 2026 out-of-pocket maximum, check for these issues before paying:
- Multiple J3399 units billed for one treatment: Zolgensma is a single one-time dose, so the billing units should equal 1.
- Out-of-network facility or specialty pharmacy billed even though the plan approved an in-network Novartis treatment center.
- Prior authorization approved for one site of care but the infusion billed at another, which triggers a denial.
- Charged above the plan's 2026 out-of-pocket maximum; once it is met, covered in-network services should cost $0.
- Itvisma and Zolgensma confused on the claim, which have different products, ages, and prices.
- CopayAssist not applied to the claim even though the patient is commercially insured; ask the treatment center to submit the explanation of benefits.
Frequently Asked Questions
Is there a generic or biosimilar for Zolgensma?
No. As of 2026, no generic or biosimilar of Zolgensma (onasemnogene abeparvovec-xioi) is approved, and none is expected soon because gene therapies are complex biologics. Itvisma (onasemnogene abeparvovec-brve) is a separate Novartis product for ages 2 and older, not a biosimilar. The lower-cost alternatives are chronic drugs, Spinraza (nusinersen) and Evrysdi (risdiplam), which work differently and are taken for life. Discuss which fits the child's age and SMA type with the neurologist.
How do I apply for the Novartis patient assistance program for Zolgensma?
Call Novartis Patient Support at 855-441-4363 or visit pap.novartis.com. Five steps: (1) confirm the right program with a case coordinator, (2) have the neurologist complete the prescriber section with the SMN1 genetic test and weight, (3) complete the patient section with income and insurance documents, (4) submit through the prescriber's office, and (5) await the decision. Common denials are income above the guideline, incomplete forms, and active coverage that still applies.
Can I use the Zolgensma copay card with Medicare or Medicaid?
No. The federal anti-kickback statute (42 U.S.C. § 1320a-7b) bars manufacturer copay assistance such as Zolgensma CopayAssist for anyone enrolled in Medicare, Medicaid, TRICARE, or VA coverage, and the 2026 program terms say the same. CopayAssist is only for commercially insured patients. If your child has Medicaid, the state program covers Zolgensma directly with a $0 to $4 nominal copay if any. Families without coverage should use the income-based Novartis Patient Assistance Foundation.
What if my insurance denies coverage for Zolgensma?
Request the written denial, then file an expedited internal appeal with a medical necessity letter, SMN1 test results, and the FDA label. Ask for a peer-to-peer review, and if it fails, request external review through your state insurance department or a Medicaid fair hearing. Under EPSDT, Medicaid must cover medically necessary treatment for children under 21. A step-therapy override or the Novartis Patient Assistance Foundation is the fallback if appeals fail.
Does the Inflation Reduction Act negotiated price apply to Zolgensma?
No. Zolgensma is not one of the Medicare drugs selected for the Inflation Reduction Act negotiation program in 2026, so no Maximum Fair Price applies. The 2026 Round-1 negotiated prices cover drugs such as Eliquis and Jardiance, and semaglutide follows in 2027. For Medicare Part D drugs generally, the 2026 out-of-pocket cap of $2,100 applies. Zolgensma patients are usually under 2, so negotiation rarely affects them anyway.
What does Zolgensma cost without insurance at the pharmacy counter?
Zolgensma has no pharmacy counter price in 2026. Walmart, Costco, Kroger, CVS, and Walgreens do not stock it, and GoodRx lists no coupon price. The Novartis list price is $2,125,000 for a one-time dose, shipped through a specialty pharmacy to a treatment center. Novartis offers payers five payments of $425,000. Uninsured families should apply to the Novartis Patient Assistance Foundation and for Medicaid or CHIP before any bill is generated.
Do I qualify for the Novartis Patient Assistance Foundation for Zolgensma?
Eligibility in 2026 depends on household income under Novartis Patient Assistance Foundation guidelines, which the foundation sets by household size and verifies at application, plus US residency, a valid prescription, and being uninsured or having coverage that has denied Zolgensma. Novartis does not publish a single federal poverty level percentage that we could verify, so confirm your household's threshold with Novartis Patient Support at 855-441-4363. Compare your income with [federal poverty level](/en/federal-poverty-level) tables and Medicaid rules first.
What is the difference between Zolgensma, Itvisma, Spinraza, and Evrysdi?
Zolgensma is a one-time intravenous gene therapy for children under 2, listed at $2,125,000 in 2026. Itvisma is a one-time intrathecal gene therapy for ages 2 and older, listed at $2,590,000. Spinraza (nusinersen) is an intrathecal injection given repeatedly for life, and Evrysdi (risdiplam) is a daily oral liquid. Each has different coverage criteria, prior authorization rules, and formulary tier placement, so ask the plan which is covered.
